Volpara Solutions expands relationship with GE Healthcare

Return to eHealthNews.nz home page

Volpara Solutions has announced the launch of an expanded agreement enabling the worldwide distribution of its industry-leading VolparaDensity software by GE Healthcare.

Now installed in more than 35 countries, the VolparaDensity clinical application analyses mammograms using machine learning to provide radiologists with automated, objective and volumetric breast density assessments and a breast density category shown to correlate to BI-RADS 4th and 5th editions.

With more than 100 peer-reviewed papers and more than 250 publications, VolparaDensity is the most clinically validated breast density assessment software in the world. It is CE-marked and cleared by the FDA, Health Canada and the TGA.

Having an objective and validated measure of breast density allows providers to deliver personalised breast care to their patients by easily identifying women with dense breasts. Such women have an increased risk of developing breast cancer and are also at a greater risk of having a cancer go undetected using conventional 2D and 3D mammography.

Since dense breast tissue and cancer appear white on a mammogram, women with dense breasts may benefit from additional screening such as that delivered by the GE Invenia® Automated Breast Ultrasound. ABUS has been shown to find small, invasive cancers missed by mammography.

“We have had a very productive partnership with GE over the past several years,” says Volpara Solutions CCO and president Mark Koeniguer.

“We are thrilled to expand our agreement beyond the US market, working with GE Healthcare to offer customers a well-researched and widely adopted breast density assessment tool to help them deliver excellent breast health care. Providing an accurate and consistent assessment of breast density is becoming increasingly important to identify women at high risk of developing breast cancer.

“We are excited to expand access to VolparaDensity as part of our product portfolio,” states GE Healthcare general manager of Automated Breast Ultrasound Luke Delaney.

“Now, our customers outside the US will also have access to a proven technology that will help them identify women who may benefit from a supplemental screening modality, such as the Invenia ABUS.”

St Luke’s University Bethlehem health network section chief of women’s imaging Joseph P. Russo says, “There are still certain signs of breast cancer that are best seen on a mammogram, which is why the Invenia ABUS is used in addition to mammography. ABUS screening helps find cancers hiding in dense tissue.

“Accurate density measurements and quality imaging are very important in breast cancer detection. I encourage women to learn their breast density, understand their risk and talk to their healthcare providers to get the personalised healthcare they need.”

Source: Volpara media release, 22 March 2019

Sector updates are provided by organisations to eHealthNews.nz and have not necessarily been edited or checked for accuracy. Any queries should be directed to the organisation issuing the release.

Do you have an item to add to sector updates?

Email your information to us at updates@hinz.org.nz

Return to eHealthNews.nz home page